article · Afro-Egyptian Journal of Infectious and Endemic Diseases
Background and study aim: Portal hypertension is abnormal increase in portal pressure. Vasoreactivity, vascular remodeling, and hepatic fibrosis contribute to increased intrahepatic resistance. β blockers decrease cardiac output and mediate splanchnic vasoconstriction. Statins have antioxidant, antiproliferative, and anti-inflammatory properties. We aimed to assess portal vein pressure using Doppler ultrasound in cirrhotic patients before and after atorvastatin administration. Patients and Methods: This study was conducted on 58 patients Randomized controlled study was done at the hepatology gastroenterology and infectious diseases department of Kafrelsheikh University Hospital on 40 cirrhotic patients who were randomly assigned to either: Group A: included 20 cirrhotic patients who were administered 20 mg of atorvastatin and 40 mg of propranolol daily for two months (n=20) or Group B: patients who received 40 mg of propranolol alone daily for two months (n=20). Clinical and laboratory evaluation, abdominal Doppler ultrasound and upper endoscopy was done at the start and after two months. Results: There was a significant difference in portal vein diameter before and after treatment (P-value = .039). Portal vein velocity, portal vein flow volume, hepatic artery resistance index, and hepatic artery pulsatility index showed significant difference between both groups. There was a significant difference in endoscopic grading before and after treatment (P value = .000). Conclusion: For lowering portal hypertension, atorvastatin and propranolol is more effective than propranolol alone .
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/aeji.2021.94017.1176
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.